After gaining steady traction in 2024, the U.S. life sciences capital markets experienced a pronounced pullback in 2025. IPO activity declined sharply, with biotech offerings falling to a ten-year low and a prolonged period with minimal IPO activity. Venture funding and deal volumes contracted as market uncertainty, underperformance of prior IPO cohorts, geopolitical volatility and evolving regulatory dynamics weighed on investor sentiment. Many companies preparing for public offerings chose to delay, awaiting clearer economic signals and increased stability across the FDA, NIH and SEC landscapes.
Meanwhile, the industry’s innovation engine remained active. The FDA approved 46 novel therapies in 2025—over half for rare diseases—with continued emphasis on oncology, non-opioid pain treatment, overdose prevention and timely access to generics. This scientific progress aligns with ongoing digital transformation, where cloud computing and generative AI are reshaping R&D productivity, operational decision-making and drug development timelines.
From a regulatory standpoint, the SEC maintained heightened scrutiny of life sciences disclosures throughout 2024–2025, emphasizing granular, transparent reporting on drug pipelines, clinical developments, strategic partnerships and risk factors. At the same time, overall SEC comment volume declined significantly, driven primarily by reduced IPO activity and fever Form S-1 filings during the period. Recent rulemaking—including cybersecurity governance, clawbacks, disclosure modernization, AI-related compliance expectations and evolving requirements for issuers—continues to reinforce the need for robust internal controls, accurate data and investor-centric disclosures.
As life sciences companies navigate shifting capital markets and regulatory frameworks, understanding recent SEC comment trends is critical to maintaining compliance and avoiding filing delays. Proactive alignment with SEC expectations will be essential to avoiding filing delays, maintaining investor confidence and preparing for an anticipated market recovery in 2026.
Our 2024–2025 report, Under the Microscope: An Analysis of SEC Comment Letter Trends Among Middle-Market and Pre-IPO Life Sciences Companies, examines SEC comments issued on Forms S-1, 10-K, 10-Q and 20-F submitted by life sciences issuers during the review period from May 1, 2024, through April 30, 2025




